

June 14th, 2021

World Journal of Clinical Oncology. Manuscript NO: 64954

Title: Evidence-Based Approach to the Treatment of Esophagogastric Junction Tumors

Dear Editor

World Journal of Clinical Oncology

Thank you very much for revising our manuscript and for your interest in publishing this work in the World Journal of Clinical Oncology. We have responded directly to all points raised by the reviewers (our response in **bold**). Please find attached a copy of the revised manuscript with all changes highlighted. We think the peer-review process significantly improved the quality of our work and we hope it will now pass editorial scrutiny.

Sincerely,

Francisco Schlottmann MD MPH

Affiliate Professor

Department of Surgery

Hospital Aleman of Buenos Aires

Av. Pueyrredon1640, Buenos Aires, Argentina

fschlottmann@hotmail.com

Office: 54911-4827-7000 (2808)

Reviewer #1:

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Minor revision

Specific Comments to Authors: I salute the authors work in this enlightening review. This is however not the only review on this topic.

Thank you very much for your comments.

(1) *Science editor*: 1 Scientific quality: The manuscript is a narrative review of Treatment of Esophagogastric Junction Tumors. The topic is within the scope of the WJGO. (1) Classification: Grade B; (2) Summary of the Peer-Review Report: “This is however not the only review on this topic”. (3) Format: There is 1 table, summarizing the advantages and disadvantages of the main surgical approaches. (4) References: A total of 48 references are cited, including 11 references published in the last 3 years; the format of references is not completely/always consistent with the journal policy. (5) Self-cited references: There are 3 self-cited references overall. The self-referencing rates is less than 10%. 2 Language evaluation: Classification: Grade B. 3 Academic norms and rules: The authors need to provide the signed Conflict-of-Interest Disclosure Form and Copyright License Agreement. No academic misconduct was found in the Bing search. 4 Supplementary comments: This is an invited manuscript. A very similar topic was published on WJGO in 2019. However, as noticed by the reviewer as well, there are similar reviews in the last few years. Moreover, the authors should clarify the new information provided by this paper, including any future perspective and/or ongoing trials. 5 Issues raised: The author should revise references to precisely adhere to the BPG journals rules. Additional table(s) to support the evidence-based approach of this review would be advisable. 6 Re-Review: Not Required. 7 Recommendation: Transferring to World Journal of Clinical Oncology

Thank you very much for all your comments.

The manuscript was modified following the reviewer and science editor suggestions.